People: Keryx Biopharmaceuticals Inc (KERX.PH)

KERX.PH on Philadelphia Stock Exchange

13.22USD
23 Jan 2015
Change (% chg)

$-0.07 (-0.53%)
Prev Close
$13.29
Open
$13.16
Day's High
$13.36
Day's Low
$13.06
Volume
18,912
Avg. Vol
5,812
52-wk High
$18.37
52-wk Low
$11.55

Search Stocks

Summary

Name Age Since Current Position

Michael Tarnok

59 2009 Independent Chairman of the Board

Ron Bentsur

49 2009 Chief Executive Officer, Director

James Oliviero

38 2009 Chief Financial Officer, Treasurer, Corporate Secretary

Gregory Madison

46 2014 Chief Operating Officer, Executive Vice President

Brian Adams

2014 Vice President, General Counsel

Thomas Edwards

2014 Vice President - US Sales

Abraham Ceesay

2014 Vice President of Marketing

Daniel Olmstead

2014 Vice President - Payer Access

Amit Sharma

2013 Vice President - Medical Affairs

Amy Sullivan

2014 Vice President - Corporate Development and Public Affairs

Douglass Laidlaw

2013 Director - Medical Affairs

Kevin Cameron

45 2007 Independent Director

Joseph Feczko

65 2010 Independent Director

Wyche Fowler

73 2006 Independent Director

Jack Kaye

70 2006 Independent Director

Daniel Regan

50 2013 Independent Director

Biographies

Name Description

Michael Tarnok

Mr. Michael P. Tarnok serves as Independent Chairman of the Board of Keryx Biopharmaceuticals Inc. He has served on our Board of Directors since September 2007, and as Chairman of the Board since June 2009. Mr. Tarnok served as our interim chief executive officer from April 2009 to May 2009. A seasoned finance and operational executive, Mr. Tarnok joined the Board with extensive pharmaceutical industry experience in a wide range of functional areas. Mr. Tarnok spent the majority of his career at Pfizer Inc., which he joined in 1989 as Finance Director — US Manufacturing, and from 2000-2007, served as Senior Vice President, Finance in Pfizer’s U.S. Pharmaceuticals Division. In this position, Mr. Tarnok handled all finance responsibilities for the division, including contracting, trade management, forecasting of significant product launches and Sarbanes-Oxley compliance. Prior to joining Pfizer, Mr. Tarnok worked primarily in financial disciplines for ITT Rayonier, Inc., Celanese Corporation and Olivetti Corporation of America. Mr. Tarnok earned an M.B.A. in Marketing from New York University and B.S. in Accounting from St. John’s University.

Ron Bentsur

Mr. Ron Bentsur is no longer serve as Chief Executive Officer, Director of Keryx Biopharmaceuticals, Inc., effective May 30, 2015. He has served as our Chief Executive Officer since May 20, 2009, and has served on our Board of Directors since June 16, 2009. Prior to joining Keryx, Mr. Bentsur served as Chief Executive Officer of XTL Biopharmaceuticals, Inc. (“XTL”), a position he held from January 2006 until April 2009. Prior to his tenure at XTL, Mr. Bentsur was with Keryx from 2000-2006, serving as our Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October 2000, Mr. Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr. Bentsur worked as an investment banker in New York City, most of this period at ING Barings Furman Selz. Mr. Bentsur holds a B.A. in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an MBA, Magna Cum Laude, from New York University’s Stern Graduate School of Business. Mr. Bentsur is a Director of Stemline Therapeutics, Inc., a public biotechnology company.

James Oliviero

Mr. James F. Oliviero, III, is Chief Financial Officer, Treasurer, Corporate Secretary of Keryx Biopharmaceuticals Inc. He has served as our Chief Financial Officer since April 2009 and previously served as our Vice President, Finance since March 2008. From May 2003 until March 2008, Mr. Oliviero served as Keryx’s Controller, where he was involved in all capital raising, licensing and acquisition transactions. Since joining Keryx, Mr. Oliviero has also been in charge of leading Keryx’s compliance with SEC rules and regulations and other corporate governance matters. From August 1999 until May 2003, Mr. Oliviero served as Director of Finance for ACCESS Oncology, Inc., a privately-held biotechnology company. From July 1997 to August 1999, Mr. Oliviero was an investment banker at ING Barings Furman Selz in New York City, where he worked on various mergers and acquisitions and equity and debt transactions. Mr. Oliviero is a CFA charterholder and holds a B.B.A. in Finance with Highest Distinction from Emory University’s Goizueta Business School.

Gregory Madison

Mr. Gregory P. Madison has been appointed as Chief Executive Officer of Keryx Biopharmaceuticals, Inc., effective May 31, 2015. Prior to joining Keryx, Mr. Madison served as the Executive Vice President and Chief Commercial Officer of AMAG Pharmaceuticals where he led the team to significant growth in net revenues. Prior to AMAG, Mr. Madison spent 12 years at Genzyme/Sanofi developing extensive commercial and general management expertise as he progressed into roles of increasing responsibilities and leadership, culminating in his most recent role as Vice President and General Manager of the Renal division. In this role, Mr. Madison led a global organization with three marketed products with combined revenues exceeding $1 billion. Mr. Madison's prior experience in the Renal division included serving as Vice President and General Manager of the U.S. business; Vice President of U.S. sales; and Vice President of U.S. marketing where he led all pre-launch preparation for Renvela®. He holds a Bachelor of Business Administration in Finance from the University of Massachusetts, Amherst.

Brian Adams

Mr. Brian R. Adams is Vice President, General Counsel of the Company. Mr. Adams comes to the Company with significant legal and business management experience within the pharmaceutical industry. Mr. Adams joins the Company from Algeta ASA, where he served as its General Counsel, with oversight of all global legal matters, corporate governance, alliance management and strategic transactions, including the highly successful launch of Xofigo® in prostate cancer, resulting in a $2.9B acquisition bid for Algeta by Bayer AG. Prior to joining Algeta in 2012, Mr. Adams spent six years as an in-house counsel for Genzyme Corporation and AVEO Oncology. Throughout his career, Mr. Adams has provided domestic and international legal support for product development, operations, commercialization, securities, healthcare compliance and licensing/M&A transactions. Prior to joining Genzyme, Mr. Adams practiced in the Boston office of Bingham McCutchen LLP, where he advised private equity sponsors, biotech and other emerging technology companies on a broad range of corporate matters and financing transactions. Mr. Adams received a BA from Harvard University and a law degree (JD) from the Catholic University of America's Columbus School of Law.

Thomas Edwards

Mr. Thomas M. Edwards is Vice President - US Sales of the Company. With a pharmaceutical sales career spanning more than 22 years, Mr. Edwards brings a strong background in sales management, training and leadership development, with extensive product launch experience across multiple specialty indications. Over the course of his career, Mr. Edwards has built and led high-performing teams that have contributed to the overall success of specialty pharmaceutical products at Eli Lilly, Genentech and Genzyme. Mr. Edwards comes to the Company from Genzyme Corporation, where, since 2006, he has served in positions of increasing leadership responsibility, culminating in the role of Head of US Sales for the Metabolic and Cardiovascular division. Mr. Edwards received his Bachelors of Science in Business Administration from Boston University.

Abraham Ceesay

Daniel Olmstead

Mr. Daniel W. Olmstead is Vice President - Payer Access of Keryx Biopharmaceuticals, Inc. Mr. Olmstead brings more than 25 years of healthcare experience, with the majority of this time spent in a variety of managed market roles, including reimbursement access, contracting, and product launch planning and execution. Prior to joining the Company, Mr. Olmstead was a National Account Director for Walgreen Co. (NYSE:WAG), where he represented all Walgreens business units with Express Scripts, its largest volume retail client. Prior to joining Walgreens in 2012, Mr. Olmstead spent more than 7 years with Genzyme/Sanofi, ultimately rising to Senior Director, Corporate Accounts. During his tenure at Genzyme/Sanofi, Mr. Olmstead served in roles of increasing responsibility within the Renal Division, including coverage of key national and regional health plans, managed markets product launch planning, and playing an integral role in establishing Renal pricing and contracting strategies for Renagel(R) /Renvela(R) , Hectorol(R) and other products. Mr. Olmstead received his Bachelor's degree from the University of Michigan, Ann Arbor.

Amit Sharma

Mr. Amit Sharma, M.D., has been appointed as Vice President - Medical Affairs of KERYX BIOPHARMACEUTICALS, INC. Recently, Dr. Sharma was Medical Director, Medical Affairs, at Reata Pharmaceuticals. From 2005-2012, Dr. Sharma served as a Medical Director and Senior Advisor for Liberty Dialysis, LLC, a medium-size dialysis organization with over 300 dialysis clinics. Liberty was sold in 2011 to Fresenius Medical Care AG for $1.7 billion. From 2001 to 2005, Dr. Sharma served as the Director of the Dialysis Unit and of the Chronic Kidney Disease Clinic for the Naval Medical Center, San Diego. Dr. Sharma received his medical degree from Louisiana State University Medical Center-New Orleans. He completed his fellowship in Nephrology and Hypertension from University of California in San Diego in 2001.

Amy Sullivan

Ms. Amy B. Sullivan is Vice President - Corporate Development and Public Affairs of the Company. Ms. Sullivan has more than two decades of experience working with life science companies at every stage of development, helping organizations to position and differentiate themselves and their products in competitive environments. Most recently, and since 2009, Ms. Sullivan served as Vice President of Investor Relations and Corporate Communications for AMAG Pharmaceuticals, overseeing the company's investor relations, public relations, and employee communications activities. Previous experience includes Idenix Pharmaceuticals, Genencor International, Perkin Elmer and Thermo Fisher. Ms. Sullivan holds a Masters in Business Administration degree from Bentley University and her Bachelor of Science degree from Salem University.

Douglass Laidlaw

Dr. Douglass H. Laidlaw, Ph.D. is Director - Medical Affairs of Keryx Biopharmaceuticals, Inc. Dr. Laidlaw joins the Company from Genzyme/Sanofi (NYSE:SNY), where since 2007 he has worked in the Medical Affairs division, most recently serving as National Director, Medical Science Liaisons (MSL) of the Renal Division. During his tenure at Genzyme/Sanofi, Dr. Laidlaw was well recognized for the strategic development and implementation of many key projects contributing to the success of the Renal business unit, notably initiatives surrounding prelaunch activities and generating scientific support aimed at increasing awareness of acute and chronic kidney disease and its sequelae. Dr. Laidlaw has extensive experience recruiting, managing and leading field based teams of MSLs. Dr. Laidlaw earned his Ph.D. in Physiological Sciences from the University of Arizona. His academic research career included positions in Biomedical Engineering at The Cleveland Clinic Foundation and in the Department of Integrative Physiology at the University of Colorado, Boulder. Previous to his employment with Genzyme, from 2006-2007, he held the position of Associate Director Medical Affairs, Medical and Education Liaisons with Neurocrine Biosciences and was a core member of the team responsible for creating their Medical Affairs infrastructure. Prior to that time, from 2003-2006, he was a Senior Medical Science Liaison at Serono. He began his career in the biopharmaceutical industry as a Regional Medical Liaison with Organon.

Kevin Cameron

Mr. Kevin J. Cameron is an Independent Director of Keryx Biopharmaceuticals, Inc. Mr. Cameron has more than ten years of corporate governance experience. Mr. Cameron is currently Chief Executive Officer of Ionetix Corporation, a privately-held medical device company. Prior to joining Ionetix Corporation, Mr. Cameron was a co-founder and president of Glass Lewis & Co. LLC, a leading provider of corporate governance services to institutional investors. Previously, Mr. Cameron was employed in various capacities by Moxi Digital and NorthPoint Communications. Mr. Cameron started his career as an attorney with the law firm of Kellogg, Huber, Hansen, Todd & Evans in Washington D.C., and also served as a law clerk for the United States Court of Appeals for the District of Columbia Circuit. Mr. Cameron holds a law degree from the University of Chicago and an undergraduate degree from McGill University. Mr. Cameron also serves as a board member of Ecotality, Inc.

Joseph Feczko

Dr. Joseph M. Feczko, M.D., is an Independent Director of Keryx Biopharmaceuticals, Inc. Dr. Feczko is a seasoned pharmaceutical executive, with broad industry experience across the spectrum of medical, regulatory and operational affairs. Dr. Feczko was, until his retirement in May 2009, Senior Vice President and Chief Medical Officer (CMO) of Pfizer Inc. and member of the Executive Leadership Team with global responsibilities for all aspects of the company’s medical, regulatory and safety activities. Dr. Feczko served Pfizer in both New York and the United Kingdom since 1982, where he held positions of increasing responsibility in clinical research and regulatory affairs and safety, culminating in the role of Chief Medical Officer. Dr. Feczko is board-certified in Internal Medicine and Infectious Diseases. He has a B.Sc. degree from Loyola University Chicago, and an M.D. from the University of Illinois College of Medicine. Dr. Feczko also serves on the board of directors of ChemoCentryx Inc., the Accordia Global Health Foundation and the Technical Expert Committee for Trachoma on the International Trachoma Initiative of the Task Force for Global Health, and was a member of the governing board of the Technology Strategy Board of the United Kingdom until June 2011. Dr. Feczko also serves as chairman of the board of directors of Cardoz Pharmaceuticals AB (Stockholm, Sweden), a member of the Supervisory Board of uniQure Biopharma B.V. based in The Netherlands, and of Cytheris, S.A. based in France.

Wyche Fowler

Senator Wyche Fowler, Jr., J.D., is an Independent Director of Keryx Biopharmaceuticals, Inc. Senator Fowler served for 16 years in the United States Congress representing the state of Georgia, including service in the United States Senate from 1987 to 1993. Following his service as a Senator, Senator Fowler served as the U.S. Ambassador to the Kingdom of Saudi Arabia from 1996 through 2001. He received his B.A. in English from Davidson College, a J.D. from Emory University and honorary degrees from Hofstra University, Davidson College and Morris Brown College. Prior to his election to Congress, he practiced law in Atlanta, Georgia for eight years. He is currently engaged in an international business and law practice and serves as Chairman Emeritus of the Middle East Institute, a non-profit research foundation in Washington, D.C. Mr. Fowler also serves on the board of directors of Shubert Theaters, the Shubert Foundation, Brandywine Realty Trust and ZIOPHARM Oncology, Inc.

Jack Kaye

Mr. Jack Kaye, CPA., is an Independent Director of Keryx Biopharmaceuticals, Inc., since September 2006. Mr. Kaye began his career at Deloitte LLP, an international accounting, tax and consulting firm, in 1970, and was a partner in the firm from 1978 until May 2006, when he retired. At Deloitte, Mr. Kaye was responsible for serving a diverse client base of public and private, global and domestic, companies in a variety of industries. Mr. Kaye has extensive experience consulting with clients on accounting and reporting matters, private and public debt financings, SEC rules and regulations and corporate governance/Sarbanes-Oxley issues. In addition, he has served as Deloitte’s Tri-state liaison with the banking and finance community and assisted clients with numerous merger and acquisition transactions. Prior to retiring, Mr. Kaye served as Partner-in-Charge of Deloitte’s Tri-State Core Client practice, a position he held for more than twenty years. Mr. Kaye previously served on the board of directors of Tongli Pharmaceuticals (USA), Inc., a China-based pharmaceutical company and Balboa Biosciences, Inc., a privately held biotech company. Mr. Kaye earned a B.B.A. from Baruch College and is a Certified Public Accountant.

Daniel Regan

Mr. Daniel P. Regan is an Independent Director of Keryx Biopharmaceuticals, Inc. He joins the Keryx Board of Directors with broad pharmaceutical leadership experience across the spectrum of global commercialization, sales and marketing of novel therapies for the treatment of patients with chronic kidney disease. From 1999 to 2011, Mr. Regan held positions of increasing responsibility at Genzyme/Sanofi (NYSE:SNY) multi-functional teams in sales, marketing and commercialization of the renal products. Mr. Regan's career at Genzyme included his appointment as Global General Manager, Senior Vice President of the Renal franchise, where he was directly responsible for all aspects of worldwide renal commercial operations, including the Renagel(R) /Renvela(R) phosphate binder franchise and the worldwide launch of Renvela(R) , growing the renal franchise to global revenue approaching $1 billion. Mr. Regan is currently Chief Commercial Officer of Intercept Pharmaceuticals (Nasdaq:ICPT). From 2011 to 2012, Mr. Regan served as Chief Commercial Officer of Inspiration Biopharmaceuticals, which sold its main asset to Baxter International. Mr. Regan received his Bachelor of Arts in Economics from the University of Massachusetts in 1988.
Search Stocks